CYCLOTRON GUADELOUPE CIMGUA

What CYCLOTRON GUADELOUPE CIMGUA does

CIMGUA (Centre d'Imagerie Moléculaire de Guadeloupe) operates the first integrated cyclotron-PET molecular imaging facility in the Caribbean, located in Les Abymes, Guadeloupe. The center combines a 12 MeV cyclotron (ISOTRACE by PMB) for on-site radioisotope production, a synthesis laboratory for radiopharmaceutical manufacturing, a European Pharmacopoeia-compliant quality control laboratory, and a PET-scan imaging department on a single site. It produces two radiopharmaceutical products—18F-FDG (Fluorodeoxyglucose) for oncology and inflammatory disease diagnostics, and 18F-Choline, added in 2021, for prostate cancer follow-up—and administers them directly to patients for diagnostic PET imaging through two exam types (TEP 18F-FDG and TEP 18F-Choline).

The center was inaugurated in June 2018 following a citizen petition with more than 27,000 signatures, with founding financing provided by the Conseil Régional and Conseil Départemental de Guadeloupe. It serves the Guadeloupe population and the broader Caribbean region, eliminating the need for patients to travel to mainland France for advanced molecular imaging—a particularly acute need given Guadeloupe's among the world's highest prostate cancer rates. Revenue is generated through PET-scan examination fees reimbursed via the French national health insurance (Sécurité sociale) and complementary mutuelles. The go-to-market is sales-led and referral-driven: physicians prescribe TEP-Scan examinations, patients arrive at the facility with referral documents, and CIMGUA handles patient intake, examination, and follow-up coordination with referring physicians, including collaboration with the CHU (university hospital) for cancer research initiatives.

Operationally, CIMGUA treated 3,158 patients through November 2022 over 205 activity days, an increase of 367 patients versus the prior year, despite reported treasury difficulties. The center employs roughly 7 specialized staff covering cyclotron operation, radiopharmacy, quality assurance, radiation protection, and patient imaging. An R&D laboratory extension—financed by the European Regional Development Fund (FEDER), groundbreaking March 17, 2022, and planned for Q1–Q2 2024 commissioning—is intended to enable development of new tracers including Carbon-11 and Gallium-68, signaling a deliberate move from pure diagnostic service toward applied radiochemistry R&D. Pricing is not publicly disclosed and there is no evidence of formal venture capital or private equity ownership.

Name

CYCLOTRON GUADELOUPE CIMGUA

Legal name

Centre d'Imagerie Moléculaire de Guadeloupe

Website

https://badger-potato-pfbs.squarespace.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

CIMGUA operates the Caribbean's first molecular imaging center in Guadeloupe, combining a 12 MeV cyclotron, radiopharmacy, and PET-scan facility on one site. It produces 18F-FDG and F18-Choline radiopharmaceuticals and provides diagnostic PET imaging to Guadeloupe and broader Caribbean patients, primarily for cancer.

Ownership category

akta.pro rank

Product category

Molecular Imaging / Nuclear Medicine Services

NAICS

Diagnostic Imaging Centers (621512), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAFAKAB

Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology)

Healthcare & Life Sciences/Healthcare Providers & Systems/Diagnostic & Imaging Centers

SECONDARYHLAIAGAE

Radiopharmacy Compounding & Dispensing (Hospital/Commercial)

Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

SECONDARYHLAIAGAI

Nuclear Medicine Clinical Services & Therapy Centers

Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

SECONDARYHLAIAGAD

Radioisotope Production (Reactor/Cyclotron/Gamma)

Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

SECONDARYHLAHABAE

Nuclear Medicine & Molecular Imaging (SPECT/PET)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

• Molecular imaging services
• PET scan diagnostics
• Radiopharmaceutical production
• Cyclotron radioisotope production
• Nuclear medicine imaging

Headquarters

HQ city

Abymes

HQ country

Guadeloupe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D

Revenue model

1. Medical Imaging Services: The center provides PET-scan examinations (TEP 18F-FDG and TEP 18F-Choline) to patients referred by healthcare providers. Revenue is generated through the French healthcare system (Sécurité sociale) and complementary health insurance (mutuelle) reimbursements. The center has faced treasury challenges despite activity growth since opening.
2. Radiopharmaceutical Production: On-site production of radiopharmaceuticals (FDG and F18-Choline) for internal use in patient examinations. While produced on-site, these are part of the diagnostic service offering rather than a separate commercial product line.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

CIMGUA operates the first molecular imaging center in the Caribbean, integrating an on-site 12 MeV cyclotron for radioisotope production, a radiopharmacy producing 18F-FDG and 18F-Choline radiopharmaceuticals, a quality control laboratory, and PET-scan imaging. The center performs two types of PET examinations (18F-FDG and 18F-Choline) for the diagnosis and monitoring of cancer and inflammatory pathologies, serving patients in Guadeloupe and the broader Caribbean region.

Product overview

CIMGUA is a molecular imaging center offering an integrated on-site system combining a 12 MeV cyclotron (ISOTRACE by PMB), an internal pharmacy, and PET scan capabilities. The center produces two radiopharmaceutical products: 18F-FDG (fluorodeoxyglucose) and 18F-Choline, both synthesized in their synthesis laboratory and verified by their quality control laboratory before patient administration. The center performs PET examinations for diagnosis and monitoring of cancer and inflammatory conditions, serving patients from Guadeloupe and the wider Caribbean. A research and development laboratory expansion is underway to develop new tracers.

Differentiator

Problem solved

Functional benefit

Products and services

• PET Scan (TEP-Scan) Positron emission tomography medical imaging examination for diagnosis and monitoring of primarily oncological and inflammatory pathologies. The center performs two types of PET exams: 18F-FDG PET and 18F-Choline PET.
• 18F-FDG (Fluorodeoxyglucose) radiopharmaceutical The most widely used radiopharmaceutical in nuclear medicine worldwide, marked with Fluor 18. Used at CIMGUA for diagnosis and monitoring of oncological and inflammatory pathologies. Synthesized in 30 minutes in the on-site synthesis laboratory.
• 18F-FCH (F18-Choline) radiopharmaceutical Fluorine-18 labeled choline radiopharmaceutical authorized in 2021 for medical production. Specifically used at CIMGUA for follow-up of prostate cancer patients. Synthesized in 45 minutes in the on-site synthesis laboratory.

Quantifiable outcome

• 3,158 patients treated in 2022 (excluding December), representing 367 additional patients compared to previous year
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• PMB (PMB SA)coreTechnology or IntegrationPMB delivered and installed the ISOTRACE cyclotron at CIMGUA. The cyclotron is a key piece of equipment enabling on-site production of Fluorine-18 radioisotopes for medical imaging. PMB is a specialized manufacturer of particle accelerators for medical applications.
• CHU (Centre Hospitalier Universitaire)coreStrategic or Co-development PartnerCollaboration with the university hospital center for medical research and the fight against cancer in the Caribbean. CHU teams work with CIMGUA staff on research and cancer treatment initiatives.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Telix Pharmaceuticals: Radiopharmaceutical company developing and commercializing diagnostic and therapeutic agents, including PSMA-targeted PET tracers for prostate cancer — directly overlapping CIMGUA's F18-Choline prostate cancer use case.
• NorthStar Medical Radioisotopes: U.S.-based commercial medical radioisotope producer using novel accelerator and neutron capture technologies to produce Mo-99 and other isotopes. Comparable as a non-traditional medical isotope producer building specialized production capacity, similar in spirit to CIMGUA's on-site cyclotron approach.
• Blue Earth Diagnostics: Specialty radiopharmaceutical company focused on PET imaging agents, particularly for prostate cancer (Axumin/18F-Fluciclovine) — directly comparable to CIMGUA's F18-Choline PET prostate cancer service line.
• SHINE Medical Technologies: Medical isotope producer building large-scale manufacturing capacity for Mo-99, I-131, and other isotopes used in diagnostic and therapeutic radiopharmaceuticals. Comparable on the medical isotope production technology side, though focused on reactor-based isotopes rather than cyclotron-based FDG.

Broad incumbents

• Lantheus Holdings: Specialty radiopharmaceutical company with a portfolio including PSMA and other PET imaging agents, plus a network of manufacturing and radiopharmacy operations. Directly comparable on the radiopharmaceutical product side (F18-based and emerging tracers) and overlaps on PET imaging agents.
• GE HealthCare: Global medical imaging OEM with PET/CT scanners, radiopharmacy software, and isotope production services. Comparable as a broad incumbent in PET imaging hardware and adjacent services, even though CIMGUA buys rather than competes with GE's scanners.
• Curium Pharma: One of the world's largest radiopharmaceutical producers, operating multiple cyclotrons and radiopharmacies across the U.S., Europe, and Asia. Highly comparable on the cyclotron-based FDG production and PET tracer supply side, though much larger and more geographically diversified than CIMGUA.
• Siemens Healthineers: Major PET/CT equipment manufacturer and operator of PETNET Solutions, a large network of cyclotron-based radiopharmacies producing FDG and other PET tracers globally. PETNET is a direct operational analog to CIMGUA's cyclotron-plus-radiopharmacy model.
• Bracco Imaging: Global diagnostic imaging company with a portfolio spanning contrast agents and a growing radiopharmaceutical/PET tracer business. Comparable on the broader molecular imaging and contrast/diagnostic agent side, with growing overlap in cyclotron-produced PET tracers.

Others

• PMB (parent organization of ISOTRACE cyclotron supplier): Manufacturer of particle accelerators and cyclotrons for medical and industrial applications, including the ISOTRACE 12 MeV cyclotron installed at CIMGUA. Comparable as an enabling technology supplier to CIMGUA's production platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cimgua

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CYCLOTRON GUADELOUPE CIMGUA